BioPharma Resources

Drug Trial Radar · NCT00820027

Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)

A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK0663/Etoricoxib and Ibuprofen in the Treatment of Postorthopedic Knee Replacement Surgery Pain

Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 776 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

776

Actual

Start

Dec 15, 2008

Primary completion

Dec 13, 2010

Study completion Dec 14, 2010

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jan 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of Etoricoxib compared to placebo and ibuprofen in the treatment of postoperative pain associated with unilateral total knee replacement surgery. The hypotheses for this study were that the average pain intensity difference (at rest) in participants treated with Etoricoxib (120 mg, 90 mg) is superior to placebo, the average total daily dose of morphine in participants treated with Etoricoxib (120 mg, 90 mg) is less than in participants treated with placebo, and that Etoricoxib (120 mg, 90 mg) will be generally safe and well tolerated by participants treated for pain following total knee replacement orthopedic surgery.

Conditions

  • Pain, Postoperative

Interventions

  • Etoricoxib 90 mgDrug

    One 90 mg tablet once daily

  • Etoricoxib 120 mgDrug

    Two 60 mg tablets once daily

  • Ibuprofen 600 mgDrug

    One tablet three times daily

  • Matching Placebo for Etoricoxib 120 mgDrug

    Two tablets once daily

  • Matching Placebo for Etoricoxib 90 mgDrug

    One tablet once daily

  • Matching Placebo for IbuprofenDrug

    One tablet three times daily

  • MorphineDrug

    As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection

  • OxycodoneDrug

    5 mg as needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)Time frame: Baseline and Days 1-3
  2. Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)Time frame: Days 1-3
  3. Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac FailureTime frame: Up to 21 days
  4. Percentage of Participants With at Least One Edema-Related AETime frame: Up to 21 days
  5. Percentage of Participants With at Least One Hypertension-Related AETime frame: Up to 21 days
  6. Percentage of Participants With at Least One Opioid-Related AETime frame: Up to 21 days
  7. Percentage of Participants Who Discontinued Study Drug Due to an AETime frame: Up to 7 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.